DELFI Diagnostics Appoints Charles Newton to Board of Directors
DELFI Diagnostics has appointed Charles “Charlie” Newton to its Board of Directors as the company advances its lead product, FirstLook Lung, towards a pivotal data readout and FDA submission. Newton brings nearly three decades of experience in healthcare finance and executive leadership.
Veteran biotech CFO and former healthcare investment banker joins the DELFI board as the company advances FirstLook Lung toward a pivotal data readout and FDA submission
PALO ALTO, Calif., April 27, 2026 /PRNewswire/ –– DELFI Diagnostics, Inc., developer of innovative AI-powered blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced the appointment of Charles “Charlie” Newton to its Board of Directors. Mr. Newton brings nearly three decades of healthcare finance and executive leadership experience to DELFI as the company reads out pivotal data that advances its lead product, FirstLook™ Lung, toward FDA submission and positions it for broad commercial adoption.